Clinical Trial: Efficacy and Safety of CHF 5993 100/6/12.5 μg HFA-152a pMDI in Patients With Asthma Uncontrolled on Medium Doses of Inhaled Corticosteroids in Combination With Long-acting ß2-agonists

U.S., April 24 -- ClinicalTrials.gov registry received information related to the study (NCT07546981) titled 'Efficacy and Safety of CHF 5993 100/6/12.5 μg HFA-152a pMDI in Patients With Asthma Uncontrolled on Medium Doses of Inhaled Corticosteroids in Combination With Long-acting ß2-agonists' on March 30.

Brief Summary: This is a study comparing CHF 5993 pMDI HFA-152a with CHF 1535 pMDI HFA-134a in Chinese patients with asthma uncontrolled on medium doses of ICS+LABA.

Study Start Date: May, 2026

Study Type: INTERVENTIONAL

Condition: Asthma

Intervention: DRUG: Experimental: Participant Group CHF 5993 pMDI HFA-152a

total daily dose of BDP/FF/GB:400/24/50 μg

Administration:

Two (2) inhalations twice daily(BID) (i.e., ...